Completed

3

880

US

asparaginase, ASNase, Colaspase, Crasnitin, Elspar, L-ASP, daunorubicin hydrochloride, Cerubidin, Cerubidine, daunomycin hydrochloride, daunorubicin, RP-13057, fludarabine phosphate, 2-F-ara-AMP, Beneflur, Fludara, therapeutic hydrocortisone, Aeroseb-HC, Barseb HC, Cetacort, Cort-Dome, Cortef, allogeneic bone marrow transplantation, bone marrow therapy, allogeneic, bone marrow therapy, allogenic, transplantation, allogeneic bone marrow, transplantation, allogenic bone marrow, 3-dimensional conformal radiation therapy, 3D conformal radiation therapy, 3D-CRT, filgrastim, G-CSF, Neupogen, cytarabine, ARA-C, arabinofuranosylcytosine, arabinosylcytosine, Cytosar-U, cytosine arabinoside, idarubicin, 4-demethoxydaunorubicin, 4-DMDR, DMDR, IDA, dexamethasone, Aeroseb-Dex, Decaderm, Decadron, DM, DXM, thioguanine, 6-TG, etoposide, EPEG, VP-16, VP-16-213, methotrexate, amethopterin, Folex, methylaminopterin, Mexate, MTX, cyclophosphamide, CPM, CTX, Cytoxan, Endoxan, Endoxana, aldesleukin, IL-2, Proleukin, recombinant human interleukin-2, recombinant interleukin-2, busulfan, BSF, BU, Misulfan, Mitosan, Myeloleukon

National Cancer Institute (NCI)

Childhood Acute Erythroleukemia (M6), Childhood Acute Megakaryocytic Leukemia (M7), Childhood Acute Monoblastic Leukemia (M5a), Childhood Acute Monocytic Leukemia (M5b), Childhood Acute Myeloblastic Leukemia With Maturation (M2), Childhood Acute Myeloblastic Leukemia Without Maturation (M1), Childhood Acute Myelomonocytic Leukemia (M4), Childhood Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndromes, Refractory Anemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Excess Blasts in Transformation, Refractory Anemia With Ringed Sideroblasts, Secondary Myelodysplastic Syndromes, Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies

09/06